Kornimate/medical-research-clean huggingface dataset:
close collaboration and discharge readiness

Conditions: Family Centered Care

Summary: this prospective non-randomized controlled before-after comparison study aims to evaluate the effects of the close collaboration with parents, a family-centered care intervention for nicu staff, on parents of the newborns in the neonatal intensive care unit (nicu). we focus on (1) family centered care of the nicu rated by parents, (2) parental anxiety symptoms, and (3) their discharge readiness. the intervention is planned to be implemented between december 2023 and december 2024. the investigators will collect data from parents whose newborns are admitted to the nicu before and after the intervention and compare the two groups. in most cases, the parents of the two groups belong to different cohorts.

study period pre-intervention data collection phase: september 2023 - december 2023 (planned) intervention phase: january 2024 - december 2024 (planned) post-intervention data collection phase: january 2025 - april 2025 (planned) outcome measures primary outcome: quality of family centered care rated by parents secondary outcomes: parental anxiety symptoms and parental discharge readiness data management eligible infants and their information will be identified and collected by research team members and entered into the excel file (.xlsx). data will be pseudonymized when the data is entered into the excel file. all electronic data will be destroyed 10 years after the initiation of the study. the principal investigator will be responsible for managing access to the data. we do not have a plan to make the data open in the future. statistical analysis the comparison between two continuous variables will be carried out by the student t test and, additionally, the multiple linear regression model and the logistic regression model to adjust the effect of the potential confounders. the potential confounders included in the models will be the length of stay and parents' previous mental illness. r and rstudio will be used to analyze the data.

Eligibility criteria:
inclusion criteria: * infants who have been admitted to the nicu for 2 weeks or longer exclusion criteria: * infants whose parent doesn't have japanese as their mother tongue * infants whose parent needs psychiatric consultation after birth

Keywords: staff education parental anxiety parental discharge readiness
repetitive applications of pruritogens and effects of a cutaneous-induced pain stimulation on nonhistaminergic itch perception

Conditions: Pain, Burning; Capsaicin

Summary: in this experiment, the investigators would like to test following hypotheses: the pain stimulation applied at the same time of a pruriceptive stimulus will decrease the itch perception. moreover, also the effect of the cutaneous pain stimulus location (same forearm of the pruriceptive stimulus versus the opposite forearm) on histaminergic and non-histaminergic itch will be investigated.

the phenomenon that pain inhibits pain is a well-known mechanism, but it is not known if pain is inhibiting itch. in this context, the aim of this project is to investigate the extent to which thermal or neurogenic short cutaneous pain can affect the itch perception. in particular, the project aims to understand any differences in itch perception when the painful stimulation is applied on the same forearm versus the opposite forearm. the hypothesis is that by applying a painful stimulus at the same time of an itchy stimulus, the itch sensitivity will decrease; probably due to an inhibitory process conducted by interneurons (bhlbb5 interneuron) at central level.

Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids, or other addictive drugs * previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis) musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results * lack of ability to cooperate * current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids * skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis) * moles, scars, or tattoos in the area to be treated or tested. * consumption of alcohol or painkillers 24 hours before the study days and between these * acute or chronic pain * participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
circadian rhythms and sleep-wake cycles in parkinson's disease

Conditions: Parkinson's Disease

Summary: disruption of sleep and alertness is one of the most disabling non-motor symptoms of parkinson's disease (pd). mechanisms leading to impaired sleep and alertness in pd are not well understood, and treatment options remain limited. the proposed research will examine markers of the circadian system, sleepiness and sleep quality in pd patients and healthy controls. further, the project will examine effects of bright light exposure on circadin function, sleep and alertness in pd.


Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd as defined by the united kingdom pd society brain bank criteria; 2. pd hoehn and yahr stage 2-4; 3. pittsburgh sleep quality index (psqi) score \>5 in group 1, and ≤5 in group 2; 4. epworth sleepiness scale (ess) score ≥10 in group 1, and \<10 in group 2; control participants will be matched for gender and age with pd participants. exclusion criteria: 1. atypical or secondary forms of parkinsonism; 2. cognitive impairment as determined by the mini-mental state examination (mmse) score of ≤ 26; 3. presence of depression defined as the beck depression inventory (bdi) score \>14; 4. use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible at least 4 weeks after the taper is completed; 5. use of ssris / snris antidepressants, unless the participant has been on a stable dose for at least 3 months prior to the screening; 6. use of medications known to affect melatonin secretion; 7. unstable/serious medical illness.

Keywords: parkinson's disease excessive daytime sleepiness circadian rhythms light therapy
salud en mis manos - breast and cervical cancer prevention and early detection - expansion 2

Conditions: Breast Cancer; Cervical Cancer

Summary: the purpose of this study is to increase early detection and prevention of breast and cervical cancer through education and navigation and to increase breast and cervical cancer screening and human papillomavirus (hpv) vaccination in underserved latinas.

this is an evaluation of the implementation of the salud en mis manos program. the investigators evaluate the effect of the program on increasing participant breast and cervical cancer screening and hpv vaccination using a one-group pre-post study design (2022-2024). the investigators also describe the implementation of the program during a longer time period (2020-.2024).

Eligibility criteria:
inclusion criteria: * primarily residing in the gulf coast \& lower rio grande valley county areas (or other counties in texas) * women 40 years of age and older with no mammogram in the past 2 years * women 21-65 years, with no pap test in the past 3 years * women aged 18-26 years, who have not initiated or completed the hpv vaccine series, and through age 45 years if advisory committee on immunization practices (acip) recommends the fda-approved age expansion for hpv vaccination for older individuals. exclusion criteria: * current pregnancy * have a current or prior cancer diagnosis

Keywords: cervical cancer screening breast cancer detection hpv vaccination
comparing effectiveness of steroids and methotrexate in treatment of chronic inflammatory breast disease

Conditions: Idiopathic Granulomatous Mastitis

Summary: this research study is to determine the effectiveness of prednisolone and methotrexate for igm patients over a period of one year, in terms of clinical and radiological response. recruitment will be conducted in national university hospital (nuh) for patients diagnosed with igm.


Eligibility criteria:
inclusion criteria: * women, aged between 21 and 60 years * positive diagnosis of idiopathic granulomatous mastitis based on histopathology results * willing and able to give informed consent exclusion criteria (patients who meet any of the following prerequisites will not be allowed to take part in this study): * women who are currently pregnant or breastfeeding * cognitive impairment which prevents the patient from giving voluntary consent * history of any psychiatric conditions such as depression, psychosis, schizophrenia etc. * history of cancer in the past 5 years * history of abnormal renal or liver function * history of diabetes mellitus * history of pulmonary lung disease, pneumonitis, or related conditions * hepatitis b and/or hepatitis c carrier * diagnosed with tuberculosis (positive microbiological evaluation for grocott methenamine silver stain and ziehl- neelsen stain) * any immunosuppressants or anti-inflammatory medications such as nsaids for the past 3 months * concomitant medication that may have contraindication with prednisolone and methotrexate use * hypersensitivity to components or drug products of prednisolone and methotrexate * vaccination with live virus vaccines prior to or during treatment

Keywords: breast breast conditions mastits granulomatous mastitis inflammation breast surgery rhematologist
the study of apatinib plus cik as the third line therapy for advanced lung adenocarcinoma patients with wild-type egfr

Conditions: Adenocarcinoma of Lung

Summary: the purpose of this study is to evaluate the safety and efficacy of apatinib combined with cytokine-induced killer cell (cik) vs apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type egfr

400 patients with stage iiib \& iv lung adenocarcinoma who had received surgery and chemotherapy,will be randomly divided into group a（apatinib plus cik treatment ) or group b（apatinib), and the randomize ratio will be 1:1. patients in group a will receive 3 cycles of cik treatment (every 1 year) and apatinib (continuous).patients in group b will receive only apatinib (continuous) .

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed lung adenocarcinoma * wld-type egfr * stage iiib/iv * failure to prior chemotherapy * life expectancy of more than 3 months * tissue sample desired for genomic study * age ≥ 18 years * performance status (who) \< 3 * adequate bone marrow function (absolute neutrophil count\>1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9gr/mm\^3) * adequate liver (bilirubin \< 1.5 times upper limit of normal and sgot/sgpt \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl) * presence of two-dimensional measurable disease. the measurable disease should not have been irradiated * informed consent exclusion criteria: * lung squamous cell carcinoma or other types of non-small cell lung cancer * small cell lung cancer * have previously received tkis * hemoglobin\<8.0 g/dl,white blood cell \<3 x 10\^9/l;platelet count \<75 x 10\^9/l; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times * known or suspected allergy to the investigational agent or any agent given in association with this trial * pregnant or lactating patients * known history of human immunodeficiency virus (hiv), hepatitis c virus (hcv) or treponemapallidun (tp) infection * patients who are suffering from serious autoimmune disease * patients who had used long time or are using immunosuppressant * patients who had active infection * patients who are suffering from serious organ dysfunction * patients who are suffering from other cancer * other situations that the researchers considered unsuitable for this study. * other concurrent uncontrolled illness

Keywords: cik apatinib lung adenocarcinoma
fresh vs frozen surgical sperm in ivf

Conditions: Infertility

Summary: the primary objective of this study is to determine if the use of frozen surgical testicular sperm specimens for icsi lead to different ivf outcomes when compared with the use of fresh surgical testicular sperm for icsi.

the study seeks to isolate the effect of slow freezing and thawing of surgical sperm specimens on fertilization and embryo blastulation rates by utilizing a randomized controlled split cohort protocol including men with obstructive azoospermia undergoing surgical sperm retrieval and good-prognosis female patients.

Eligibility criteria:
inclusion criteria: * females age \< 42 with an indication for ivf * females with lowest amh level 1.2 ng/ml or higher * females with fsh \< 13 miu/ml * sperm obtained via surgical retrieval (any type) for ivf only * use of comprehensive chromosome screening (ccs) to screen embryos for aneuploidy * bmi \< 35 * baseline antral follicle count of \> 8 * single embryo transfers only exclusion criteria: * anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. * contraindication to ivf * clinical indication for preimplantation genetic diagnosis (pgd) (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring detailed embryo genetic analysis) * fewer than 4 mature oocytes retrieved (will not randomize) * male partner with non-obstructive azoospermia * male partner with any karyotype other than 46,xy * male partner with history of spinal cord injury * male partner with kallman's syndrome * history of chronic oligomenorrhea * history of hydrosalpinges or adnexal mass * history of endometrial insufficiency (max endometrial thickness \< 7mm)
outcome after avascular necrosis of the femoral head in young patients

Conditions: Avascular Necrosis of the Femoral Head

Summary: 1. the course of avn between initial diagnosis and total hip replacement (tha) is analysed. the impact of early interventions versus conservative therapy in avn before tha will be evaluated. 2. the short and long term outcomes of avn patients undergoing tha with respect to complications, reoperations and quality of life are investigated. potential risk factors for adverse outcomes will be investigated.

the study is to describe the course of avascular necrosis (avn) of the femoral head from initial diagnosis and to collect data on treatment options and the further course in these cases. the duration from initial diagnosis of avn to joint replacement as total hip arthroplasty (tha) will be analysed and the course after joint replacement with potential short- and long-term complications will be evaluated. the impact of tha after avn on activities of daily living will be assessed by euroquol 5 dimensions (eq-5d-5l) and hip disability and osteoarthritis outcome score (hoos) questionnaires.

Eligibility criteria:
inclusion criteria: * mri of the hip available from diagnosis at the usb or ksbl liestal * informed consent exclusion criteria: * insufficient knowledge of project languages (english, german, french)

Keywords: total hip arthroplasty total hip replacement
retrospective and prospective follow-up of patients with primary hyperoxaluria type 1 treated with lumasiran in france.

Conditions: Patients With PH1 Treated With Lumasiran in France

Summary: primary hyperoxaluria type 1 (ph1) is a rare genetic disease caused by mutation in the agxt gene encoding the hepatic peroxisomal enzyme agt. reduced agt activity results in increased glyoxylate and oxalate production, causing the formation of kidney stones, nephrocalcinosis and renal failure. clinical trials of lumasiran have provided information on the efficacy and safety of lumasiran in the treatment of primary hyperoxaluria type 1. however, they do not provide data on long-term efficacy, safety and patient management. as part of the post-marketing follow-up of lumasiran, in agreement with the authorities, this study proposes a retrospective and prospective follow-up over 5 years of pediatrics and adults patients treated in france with a standardized clinical, biological and radiological follow-up. the main objective is to monitor the evolution of ph1 parameters and particularly oxaluria before and after treatment.


Eligibility criteria:
inclusion criteria: * patient with primary hyperoxaluria type 1 who has been treated with lumasiran, since the beginning of the atu (temporary authorization for use) and in post-marketing. exclusion criteria: * opposition of the patient or his legal representatives for minors. * not covered by social security.

Keywords: lumarisan primary hyperoxaluria type 1 (ph1) retrospective and prospective data.
caria: digital intervention for menopause symptom

Conditions: Menopause; Hot Flashes

Summary: menopause is the time of life when menstrual cycles cease. women typically spend 30-40% of their lives in menopause. individual experiences of menopause vary and although some women do not experience any significant symptoms, common symptoms include vasomotor dysfunction, vaginal dryness, mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints and sexual dysfunction. reduced quality of life can occur as a result of these symptoms. a mobile app has been developed to reduce the impact of these symptoms using a variety of behavioral change techniques including education, goal setting, motivational enhancement, social support and cognitive behavioral approaches. participants will complete self report assessments of women's symptoms and qol at baseline, 3 weeks and 6 weeks of app use.


Eligibility criteria:
inclusion criteria: - women with variable menstrual cycles (menopausal transition) or those who were more than 1 year from their last menstrual period (postmenopause) hot flash/night sweats should be experienced as problematic (as indicated by an average score of 2 or higher on three items of the hot flush rating scale elevated score on at least one measure - either depression (phq8=10 or greater, sleep (psqi of 5 or greater) or anxiety (gad7=10 or greater) own an apple device able to run the caria app english speaking exclusion criteria: * none
antihypertensive effect and safety of peptides derived from coldwater shrimp

Conditions: Hypertension; Blood Pressure

Summary: the purpose of this proof of concept study is to find out the efficacy of marealis refined peptide concentrate (rpc) from coldwater shrimp (pandalus borealis) containing ace-inhibiting peptides on blood pressure in subjects with mild or moderate hypertension.


Eligibility criteria:
inclusion criteria: * mild or moderate hypertension (systolic blood pressure 130 - 160 mmhg and diastolic blood pressure ≤ 100 mmhg) * age 30 - 75 years * body weight ≥ 60 kg * stable body weight * use of effective contraception in women of childbearing potential exclusion criteria: * body mass index ≥ 35 * antihypertensive drug treatment, regular high dose nsaid treatment and the use of cyclosporine or tacrolimus * diabetes (type 1 and 2) * anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid function, clinically significant biochemistry, any other clinically significant hematology and/or biochemistry at the investigator's discretion * cardiovascular disease (myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening) including stroke and congestive heart failure * secondary hypertension history of cancer or malignant disease within the past five years * any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subjects * fish and other seafood allergies, citrus allergy, multiple food allergies * alcohol abuse * smokers and tobacco/snuff/nicotine users * consumption of food supplements targeted to blood pressure lowering within 30 days before randomization * pregnant and lactating mothers, women, planning for pregnancy during the study * participation in clinical trials 30 days prior to this study and participation in other clinical intervention

Keywords: randomized double-blind placebo-controlled study peptide concentrate coldwater shrimp antihypertensive effect mild hypertension moderate hypertension blood pressure
direct acting antivirals for hcv infection in kidney transplant recipients

Conditions: Kidney Transplant; Complications; Hepatitis C, Chronic

Summary: chronic hepatitis c virus (hcv) infection, an important cause of morbidity and mortality worldwide, is a significant problem in kidney transplant recipients (ktrs) given its high prevalence in patients undergoing hemodialysis. interferon based regimens were cornerstone of treatment of hcv infection in the past; however, due to their low efficacy and high rates of adverse effects, they have been abandoned in the new era of direct acting antivirals (daas). several studies demonstrated the efficacy and safety of daas, yet data regarding clinical practice of these agents in ktrs is still needed. therefore, we conducted a study using our registry data to evaluate the efficacy and safety of daas in ktrs.


Eligibility criteria:
inclusion criteria: * being a kidney transplant recipient. * having a detectable level of hcv rna. * having direct acting antivirals for 12 or 24 weeks. exclusion criteria: * withdrawing or not providing consent.

Keywords: kidney transplant recipients chronic hepatitis c virus infection direct acting antivirals sofosbuvir/ledipasvir
balloon cryotherapy vs. radiofrequency ablation pain study

Conditions: Barrett Esophagus

Summary: barrett's esophagus is a condition in which the normal lining of the lower esophagus is replaced with cells that predispose an individual to development of esophageal cancer. treatment of barrett's esophagus reduces the risk of progression to cancer. treatment is provided endoscopically, via a variety of approved techniques including endoscopic mucosal resection, argon plasma coagulation, radiofrequency ablation (rfa), spray cryotherapy ablation and balloon cryotherapy ablation. a common side effect of ablation treatment is pain, thus making pain an important factor when discussing treatment options. it is speculated that balloon cryotherapy causes less pain than rfa but no head-to-head comparison trials exist to date. this multi-center, prospective cohort study aims to compare pre- and post-procedural pain for balloon cryotherapy versus rfa. providing both patients and clinicians with data from a well-designed prospective study may help guide future physician/patient treatment discussions.


Eligibility criteria:
inclusion criteria: 1. patients with dysplastic barrett's esophagus (lgd and hgd) naïve to ablation therapy presenting for ablation 2. age ≥ 18 3. ability to sign informed consent exclusion criteria: 1. prior ablation treatment for barrett's esophagus 2. pregnancy